FDA.reportPublic FDA data

adalimumab-bwwd 40 MG in 0.4 ML Auto-Injector

RxCUI
2640430
RxNorm name
adalimumab-bwwd 40 MG in 0.4 ML Auto-Injector
Display name
adalimumab-bwwd 40 MG in 0.4 ML Auto-Injector
Full name
adalimumab-bwwd 40 MG in 0.4 ML Auto-Injector
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:56

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761059Hadlimaadalimumab-bwwd351(k) InterchangeableRx2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
HADLIMAADALIMUMAB-BWWDA-S Medication Solutionsc361dd60-c88d-4f3c-b98c-79687bbc34502026-05-14Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2640430
Adalimumab-bwwdADALIMUMAB-BWWDCordavis Limitedc24655e5-796e-4127-b716-92f08d649c832025-10-17Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2640430

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 3 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
4774a951-3ce8-43b6-80b1-e6b23752aae6adalimumab-bwwd 40 MG in 0.4 ML Auto-Injector [PSN] · 0.4 ML adalimumab-bwwd 100 MG/ML Auto-Injector [SCD] · adalimumab-bwwd 40 MG per 0.4 ML Auto-Injector [SY]313These highlights do not include all the information needed to use HADLIMA safely and effectively. See full prescribing information for HADLIMA. HADLIMA (adalimumab-bwwd) injection, for subcutaneous use Initial U.S. Approval: 2019 HADLIMA (adalimumab-bwwd) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee20251017
c361dd60-c88d-4f3c-b98c-79687bbc3450adalimumab-bwwd 40 MG in 0.4 ML Auto-Injector [PSN] · 0.4 ML adalimumab-bwwd 100 MG/ML Auto-Injector [SCD] · adalimumab-bwwd 40 MG per 0.4 ML Auto-Injector [SY]33These highlights do not include all the information needed to use HADLIMA safely and effectively. See full prescribing information for HADLIMA. HADLIMA (adalimumab-bwwd) injection, for subcutaneous use Initial U.S. Approval: 2019 HADLIMA (adalimumab-bwwd) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee20260514
c24655e5-796e-4127-b716-92f08d649c83adalimumab-bwwd 40 MG in 0.4 ML Auto-Injector [PSN] · 0.4 ML adalimumab-bwwd 100 MG/ML Auto-Injector [SCD] · adalimumab-bwwd 40 MG per 0.4 ML Auto-Injector [SY]32These highlights do not include all the information needed to use ADALIMUMAB-BWWD safely and effectively. See full prescribing information for ADALIMUMAB-BWWD. ADALIMUMAB-BWWD injection, for subcutaneous use Initial U.S. Approval: 2019 Adalimumab-bwwd is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between th20251017